Form 4: CorMedix CEO Todisco Reports Equity Transactions
Insider Transaction Report
CorMedix CEO Joseph Todisco reported recent transactions involving common stock and stock options, including option exercises and tax-related dispositions.
Summary
- Joseph Todisco, CEO and Director of CorMedix Inc. [CRMD], reported changes in his beneficial ownership of company securities.
- On January 12, 2026, Todisco disposed of 17,417 shares of common stock at a price of $7.15 per share, a transaction reported late due to an inadvertent administrative error.
- On January 16, 2026, Todisco acquired 29,585 shares of common stock by exercising stock options at an exercise price of $3.38 per share, paying the exercise price in cash with no sales of stock made in this specific transaction.
- On January 17, 2026, Todisco disposed of an additional 22,665 shares of common stock at a price of $6.78 per share.
- Following these transactions, Todisco directly beneficially owns 498,999 shares of CorMedix Inc. common stock.
- Todisco also holds 411,245 unexercised stock options, granted on May 10, 2022, with an exercise price of $3.38 and an expiration date of May 9, 2032.
- A Power of Attorney was executed on January 14, 2026, appointing Beth Zelnick Kaufman as attorney-in-fact for Joseph Todisco's SEC filings.
Sentiment
Score: 6
Explanation: The filing details routine insider transactions, including option exercises and tax-related dispositions, which are common for executives. The late reporting of one transaction is a minor administrative issue, not indicative of significant operational or financial changes.
Positives
- CEO Joseph Todisco exercised a significant number of stock options (29,585 shares), converting potential value into actual equity ownership.
- The exercise price of the options ($3.38) is substantially lower than the market prices at which shares were disposed ($7.15 and $6.78), indicating a favorable gain on the exercised options.
Negatives
- A transaction on January 12, 2026, involving the disposition of 17,417 shares, was reported late due to an inadvertent administrative error.
- Dispositions of 17,417 shares and 22,665 shares occurred, which, while likely tax-related to the option exercise, represent a reduction in direct share count.
Risks
- A transaction on January 12, 2026, was reported late due to an inadvertent administrative error, indicating a minor compliance oversight.
Future Outlook
The stock options held by Joseph Todisco are scheduled to vest over four years in four equal installments on the first four anniversaries of the May 10, 2022 grant date, subject to his continued employment through the applicable vesting dates.
Management Comments
- "This transaction is being reported late due to an inadvertent administrative error." (Regarding the January 12, 2026 transaction)
- "The Reporting Person acquired stock through the exercise of options granted on 5/10/2022. The Reporting Person paid the exercise price in cash. No sales of stock were made." (Regarding the January 16, 2026 transaction)
Industry Context
This filing is a routine insider transaction report (Form 4) for a pharmaceutical/biotech company executive. Such filings are common across all industries and provide transparency into executive stock ownership and trading activities. They are typically not indicative of broader industry trends unless they reveal a pattern across multiple companies or a significant shift in executive confidence.
Comparison to Industry Standards
- NA. This filing is a standard insider transaction report and does not contain information suitable for comparison to industry-specific operational or financial benchmarks.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | Joseph Todisco granted a Power of Attorney to Beth Zelnick Kaufman to prepare, execute, submit, and file SEC Forms (ID, 3, 4, 5, 144) on his behalf. | 2026-01-14 | Streamlines compliance for Joseph Todisco's personal SEC filing obligations as an officer and director, ensuring timely and accurate submissions. |
Stakeholder Impact
- Shareholders: Provides transparency into executive stock ownership and trading, which can influence investor confidence. The exercise of options and subsequent tax-related sales are routine and generally not indicative of a significant shift in company prospects.
- Employees: The vesting schedule of options is tied to continued employment, which is a standard incentive mechanism.
Next Steps
- Future vesting of Joseph Todisco's remaining stock options on the anniversaries of the May 10, 2022 grant date.
- Ongoing compliance by Joseph Todisco with Section 16 of the Securities Exchange Act of 1934, as amended, for reporting changes in beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 2022-05-10 | Grant date of stock options to Joseph Todisco. |
| 2026-01-12 | Disposition of 17,417 shares of common stock by Joseph Todisco at $7.15 per share. |
| 2026-01-14 | Joseph Todisco executed a Power of Attorney appointing Beth Zelnick Kaufman for SEC filings. |
| 2026-01-16 | Acquisition of 29,585 shares of common stock by Joseph Todisco through option exercise at $3.38 per share. |
| 2026-01-17 | Disposition of 22,665 shares of common stock by Joseph Todisco at $6.78 per share. |
| 2026-01-20 | Date of signature for the Form 4 filing by attorney-in-fact. |
| 2032-05-09 | Expiration date of stock options held by Joseph Todisco. |
Keywords
CorMedix, CRMD, Joseph Todisco, Insider Trading, Stock Options, Form 4, SEC Filing, Beneficial Ownership, CEO, Director, Equity Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.